MedTrace Logo

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

NCT00074152 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2017-06-16

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is effective in treating women who have undergone surgery and radiation therapy for relapsed breast cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of adjuvant chemotherapy in treating women who have undergone resection for local and/or regional relapsed breast cancer.

Conditions

Interventions

DRUG

chemotherapy

Given within 10 weeks after surgery.

RADIATION

radiation therapy

Given within 6 months after surgery

Sponsors & Collaborators

  • NSABP Foundation Inc

    collaborator NETWORK

  • ETOP IBCSG Partners Foundation

    lead NETWORK

Principal Investigators

  • Stefan Aebi, MD · Inselspital Bern, Switzerland

  • Irene L. Wapnir, MD · Stanford Cancer Center, CA, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2014-02-28
Completion
2016-08-22

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Hungary
  • Netherlands
  • Peru
  • South Africa
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00074152 on ClinicalTrials.gov